BioCardia, Inc. announced completion of enrollment and collection of the primary endpoint results of the open label roll-in cohort of the CardiAMP® Cell Therapy in Chronic Myocardial Ischemia Trial.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3999 USD | +0.98% | +1.50% | -39.79% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-39.79% | 10.74M | |
+7.52% | 113B | |
+11.38% | 106B | |
-12.64% | 22.22B | |
+0.44% | 22.27B | |
-4.18% | 19.43B | |
-37.85% | 17.87B | |
-8.58% | 17.24B | |
+37.41% | 12.52B | |
-23.95% | 8.34B |
- Stock Market
- Equities
- BCDA Stock
- News BioCardia, Inc.
- BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort